Primary Hyperparathyroidism Clinical Trial
— PARAMBUOfficial title:
Feasibility of Parathyroidectomy With Exploration of 4 Parathyroid Glands in Outpatients, for Treatment of Primary Hyperparathyroidism
NCT number | NCT03732157 |
Other study ID # | K180301J |
Secondary ID | |
Status | Not yet recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 2018 |
Est. completion date | July 2019 |
The development of outpatient surgery has become a national priority, with the objective of
an ambulatory surgery rate of around 50% in 2016, whereas this rate reached only 37.7% in
2010.
In the context of the management of primary hyperparathyroidism, there are two possible
approaches. The first, which is commonly performed on an outpatient basis, consists in
approaching only the pathological gland, if it was first identified by scintigraphy and
ultrasound (which is the case in one patient in two), without exploring the others
parathyroid glands.
The reference technique consists in exploring the 4 parathyroid sites by transverse
cervicotomy. Although more invasive, it minimizes the risk of failure due to the lack of
knowledge of multi-glandular forms of the disease (15 to 20%), whose preoperative diagnosis
is difficult. This reference technique is poorly performed on an outpatient basis while it
lends itself to this type of management because of the superficial character of the operative
site, a short operating time, moderate postoperative pain, rapid return oral nutrition and
exceptional and early serious complications (delay <24 h for cervical hematoma, <24 h for
hypocalcemia and immediate diagnosis of recurrent palsy).
In this study, the investigators hypothesize that parathyroidectomy with 4-gland parathyroid
exploration is feasible by ensuring patient safety. The investigators also believe that
outpatient management will not lead to any difference after 3-month surgery, but will reduce
hospitalization costs while increasing patient satisfaction with conventional care. To do so,
the investigators carried out an observational cohort study of patients with an indication of
parathyroidectomy wo will undergo outpatient management or conventional management (stay
overnight in hospital) to inform all of these data.
Status | Not yet recruiting |
Enrollment | 140 |
Est. completion date | July 2019 |
Est. primary completion date | July 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 100 Years |
Eligibility |
Inclusion Criteria: - Patients > 18 years old - Diagnosis of primary hyperparathyroidism (inappropriate parathyroid hormone secretion compared with calcemia) - Surgical indication of parathyroidectomy with possible management outpatient or conventional hospitalization (choice of mode of care by the surgeon, after consultation with the patient) Exclusion Criteria: - Non-eligibility for outpatient surgery for general medical reasons (ASA score), determined during the consultation of preoperative anesthesia - Preoperative hypercalcemia> 3 mmol / L (due to the high risk of postoperative hypocalcemia) - History of cervicotomy for thyroidectomy or failure of parathyroid surgery - Treatment of primary hyperparathyroidism with elective surgical approach - Person under guardianship and curatorship |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of conversion or readmission to conventional hospitalization | The primary endpoint will be assessed for patients receiving outpatient management. Proportion of patients who could not discharged from hospital the same day of surgery as originally scheduled or being readmitted to conventional hospitalization within 8 days post operatively. | within 8 days postoperatively | |
Secondary | Postoperative pain evaluated using visual analogue scale (VAS) | Pain will be evaluated using visual analogue scale (VAS) . VAS score ranges from 0 to 10. A high VAS score represents a high level of pain while a low VAS score represents a low level of pain. | at day 0 post operatively | |
Secondary | Postoperative pain evaluated using visual analogue scale (VAS) | Pain will be evaluated using visual analogue scale (VAS) . VAS score ranges from 0 to 10. A high VAS score represents a high level of pain while a low VAS score represents a low level of pain. | at day 1 post operatively | |
Secondary | Postoperative pain evaluated using visual analogue scale (VAS) | Pain will be evaluated using visual analogue scale (VAS) . VAS score ranges from 0 to 10. A high VAS score represents a high level of pain while a low VAS score represents a low level of pain. | at day 8 post operatively | |
Secondary | Proportion of patients with breathing difficulty. | Dyspnea will be evaluated using the New York Heart Association (NYHA) Functional Classification. The stage of dyspnea is classified in four categories based on how much patients are limited during physical activity. Breathing difficulty will be defined by a stage of 3 on the NYHA scale. | at day 1 post operatively | |
Secondary | Proportion of patients with breathing difficulty. | Dyspnea will be evaluated using the New York Heart Association (NYHA) Functional Classification. The stage of dyspnea is classified in four categories based on how much patients are limited during physical activity. Breathing difficulty will be defined by a stage of 3 on the NYHA scale. | at day 8 post operatively | |
Secondary | Proportion of patients with compressive cervical hematoma | clinical evaluation based on the occurrence of a cervical collection that can obstruct the upper aero-digestive tract (NYHA scale dyspnea) | at day 0 post operatively | |
Secondary | Proportion of patients with compressive cervical hematoma | clinical evaluation based on the occurrence of a cervical collection that can obstruct the upper aero-digestive tract (NYHA scale dyspnea) | at day 1 post operatively | |
Secondary | Proportion of patients with compressive cervical hematoma | clinical evaluation based on the occurrence of a cervical collection that can obstruct the upper aero-digestive tract (NYHA scale dyspnea) | at day 8 post operatively | |
Secondary | Proportion of patients with hypocalcemia | Hypocalcemia will be defined as calcemia lower than 2 mmol/L or 80 mg/L | at day 1 post operatively | |
Secondary | Proportion of patients with hypocalcemia | Hypocalcemia will be defined as calcemia lower than 2 mmol/L or 80 mg/L | at 3 months post operatively | |
Secondary | Proportion of patients with recurrent nerve paralysis | Clinical evaluation based on the occurrence of voice modification with swallowing disorder | at day 0 post operatively | |
Secondary | Proportion of patients with recurrent nerve paralysis | Clinical evaluation based on the occurrence of voice modification with swallowing disorder | at day 1 post operatively | |
Secondary | Proportion of patients with recurrent nerve paralysis | Clinical evaluation based on the occurrence of voice modification with swallowing disorder | at day 8 post operatively | |
Secondary | Patients' satisfaction regarding his/her care evaluated using visual analogue scale (VAS) | Patients' satisfaction evaluated using visual analogue scale (VAS). VAS score ranges from 0 to 10. A high VAS score represents a high level of satisfaction while a low VAS score represents a low level of satisfaction. | at day 0 post operatively | |
Secondary | Patients' satisfaction regarding his/her care evaluated using visual analogue scale (VAS) | Patients' satisfaction evaluated using visual analogue scale (VAS). VAS score ranges from 0 to 10. A high VAS score represents a high level of satisfaction while a low VAS score represents a low level of satisfaction. | at day 1 post operatively | |
Secondary | Patients' satisfaction regarding his/her care evaluated using visual analogue scale (VAS) | Patients' satisfaction evaluated using visual analogue scale (VAS). VAS score ranges from 0 to 10. A high VAS score represents a high level of satisfaction while a low VAS score represents a low level of satisfaction. | at 3 months post operatively | |
Secondary | Total cost of mode of care | Total cost of hospital surgery stay and hospital readmission at 3 months | at 3 months post operatively |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03931109 -
Circulating miRNA in Primary Hyperparathyroidism
|
||
Completed |
NCT04305561 -
Preoperative Localization Strategies in Primary Hyperparathyroidism
|
N/A | |
Recruiting |
NCT03052075 -
Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism
|
||
Completed |
NCT03774771 -
Safety, Pharmacokinetics, and Clinical Effects of Cinacalcet (AMG 073) in Primary Hyperparathyroidism
|
Phase 2 | |
Recruiting |
NCT02854345 -
Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera
|
N/A | |
Completed |
NCT01222026 -
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate
|
Phase 4 | |
Recruiting |
NCT00973336 -
Primary Hyperparathyroidism: Does a Systematic Treatment Improve the Calcium and Bone Metabolism After Surgery?
|
Phase 2 | |
Completed |
NCT01530919 -
Minimally Invasive Radioguided Parathyroidectomy
|
N/A | |
Recruiting |
NCT03605472 -
Comparison of Cervical Ultrasound and Echoscintigraphy for Preoperative Localization Diagnosis in Primary Hyperparathyroidism
|
N/A | |
Completed |
NCT01306656 -
Vitamin D Repletion in Primary Hyperparathyroidism
|
Phase 4 | |
Terminated |
NCT00961701 -
Lipids Profile in Primary Hyperparathyroidism
|
N/A | |
Completed |
NCT00432939 -
Primary Hyperparathyroidism: Non-classical Manifestations
|
N/A | |
Completed |
NCT00522028 -
Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Trial
|
N/A | |
Completed |
NCT03713671 -
Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism
|
N/A | |
Recruiting |
NCT04969926 -
Natural History Study of Parathyroid Disorders
|
||
Recruiting |
NCT03039439 -
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
|
||
Completed |
NCT01996072 -
EC17 for Intraoperative Imaging for Parathyroidectomy
|
Phase 1 | |
Completed |
NCT01460030 -
An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism
|
Phase 3 | |
Enrolling by invitation |
NCT04085419 -
Osteoporosis in Primary Hyperparathyroidism
|
Phase 4 | |
Recruiting |
NCT03935984 -
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
|
Phase 4 |